The vacuum-insulated dewar, invented by Sir James Dewar in 1892 and largely unchanged in its fundamental architecture, is the storage vessel that holds every frozen embryo in clinical storage. Its performance is determined by the quality of its vacuum insulation, which degrades over time. The failure mode is silent and progressive: increased LN2 consumption, reduced holding time, and eventually temperature instability. The clinical consequence in an unmonitored or inadequately maintained vessel is sample loss that may not be detected until years after the storage failure occurred.

Modern high-capacity cryogenic storage systems, such as the CryoBank Series from Cryolab (350-1800L, with automated LN2 supply, continuous monitoring, and remote alarm integration), address these failure modes through engineering and monitoring architecture rather than manual oversight. For IVF networks and biobanks operating at scale, the case for high-capacity automated storage over multiple smaller manually managed dewars rests primarily on risk reduction rather than cost.

Cryogenic transport represents a distinct technical challenge. IATA regulations prohibit free liquid nitrogen on commercial aircraft. Vapour phase dry shippers (cryoshippers) provide the clinical solution: an absorbent matrix saturated with LN2 vapour maintains approximately -190°C without free liquid, compliant for air freight. The technical performance parameters -- holding time, charging time, temperature uniformity across the sample cavity -- vary significantly between products and warrant the same scrutiny applied to storage vessel selection.

The complete guide to cryogenic technology, covering the physics, the engineering, the applications, and the UK regulatory framework: https://cryolab.co.uk/cryogenic-technology-complete-guide/

https://cryolab.co.uk/cryogenic-technology-complete-guide/